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Impact of Functional Status on Outcomes of 
Simultaneous Pancreas-kidney Transplantation: 
Risks and Opportunities for Patient Benefit
Krista L. Lentine, MD, PhD,1 Tarek Alhamad, MD, MS,2 Wisit Cheungpasitporn, MD,3 Jane C. Tan, MD,4 
Su-Hsin Chang, PhD,2 Matthew Cooper, MD,5 Darshana M. Dadhania, MD, MS,6 David A. Axelrod, MD, MBA,7 
Mark A. Schnitzler, PhD,1 Rosemary Ouseph, MD,1 Franco H. Cabeza Rivera, MD,3 Bertram L. Kasiske, MD,8  
Kenneth J. Woodside, MD,9 and Ronald F. Parsons, MD10
INTRODUCTION
Simultaneous pancreas-kidney transplant (SPKT) offers 
the best long-term outcomes for type 1 diabetes mel-
litus associated with advanced chronic kidney disease 
(CKD) or end-stage kidney disease (ESKD).1,2 Successful 
pancreas transplant achieves insulin independence and 
good metabolic control, improving and stabilizing many 
of the complications of insulin-dependent diabetes, and 
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Background. The impact of functional status on survival among simultaneous pancreas-kidney transplant (SPKT) can-
didates and recipients is not well described. Methods. We examined national Scientific Registry of Transplant Recipients 
(SRTR) data for patients listed for SPKT in the United States (2006–2019). Functional status was categorized by center-
reported Karnofsky Performance Score (KPS). We used Cox regression to quantify associations of KPS at listing and 
transplant with subsequent patient survival, adjusted for baseline patient and transplant factors (adjusted hazard ratio, 95% 
LCLaHR95%UCL). We also explored time-dependent associations of SPKT with survival risk after listing compared with contin-
ued waiting in each functional status group. Results. KPS distributions among candidates (N = 16 822) and recipients 
(N = 10 316), respectively, were normal (KPS 80–100), 62.0% and 57.8%; capable of self-care (KPS 70), 23.5% and 24.7%; 
requires assistance (KPS 50–60), 12.4% and 14.2%; and disabled (KPS 10–40), 2.1% and 3.3%. There was a graded 
increase in mortality after listing and after transplant with lower functional levels. Compared with normal functioning, mortality 
after SPKT rose progressively for patients capable of self-care (aHR, 1.001.181.41), requiring assistance (aHR, 1.061.311.60), and 
disabled (aHR, 1.101.552.19). In time-dependent regression, compared with waiting, SPKT was associated with 2-fold mortal-
ity risk within 30 days of transplant. However, beyond 30 days, SPKT was associated with reduced mortality, from 52% for 
disabled patients (aHR, 0.260.480.88) to 70% for patients with normal functioning (aHR, 0.260.300.34). Conclusions. While 
lower functional status is associated with increased mortality risk among SPKT candidates and recipients, SPKT can provide 
long-term survival benefit across functional status levels in those selected for transplant.
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restoring kidney function prevents dialysis-related morbid-
ity.3 Overall, SPKT recipients gain increased life expectancy 
and quality of life compared with type 1 diabetic ESKD 
patients who remain on dialysis,4,5 albeit with moderately 
increased perioperative risks compared with kidney trans-
plant alone.5,6 Further, the patient population seeking SPKT 
is evolving, as improvements in diabetes care, advanced 
insulin delivery technologies, and delayed CKD progression 
have resulted in an older population living with prevalent 
disease and an expansion of SPKT to selected patients with 
type 2 diabetes.7-9 The average age of SPKT recipients in 
2017 was 43 years, compared with 38 years in 1995.10 In 
2018, 26.7% of US SPKT candidates and 23.1% of recipi-
ents were aged older than 50 years.7 As diabetic patients 
present for transplant evaluation at progressively older 
ages with concomitant higher comorbidity burdens, frailty 
and impaired functional status have become important 
considerations in clinical assessment and management.11,12
Frailty is a global measure of physical function character-
ized by decreased strength, decreased endurance, muscle wast-
ing, and lack of physiological reserve.13,14 Frailty has been 
studied extensively in patients with CKD, and, more recently, 
in kidney transplant populations, using a number of differ-
ent frailty scales and approaches.15,16 Significant associations 
between frailty and poor outcomes after kidney transplant 
have been reported, including a high risk of mortality.14,17,18 
While data on the impacts of frailty on kidney transplant out-
comes are emerging,17-20 there is a paucity of information on 
the impact of measures of frailty on pancreas transplant out-
comes, including SPKT-related outcomes. Given that SPKT is 
a high-risk procedure than kidney transplant alone,21 some 
transplant programs may avoid the additional risk of pan-
creas transplant surgery in frail diabetic patients.
The Karnofsky Performance Score (KPS), a categorical 
assessment tool for functional impairment, has been commonly 
used for many chronic disease assessments, including among 
transplant candidates and recipients.22,23 US transplant centers 
report KPS at the times of listing and transplant to the Organ 
Procurement and Transplantation Network (OPTN) national 
registry.22 KPS is a simple scale that ranks patients from normal 
functioning (100%) to dead (0%) in 10% increments. KPS is 
easily determined and nationally reported.22 Though not initially 
intended as a measure of frailty, it is the only measure among 
data collected by the Scientific Registry of Transplant Recipients 
(SRTR) that can be used as a surrogate measure. In a recent 
study of adult deceased-donor kidney transplant recipients, 
KPS at transplant was found to be an independent predictor 
of posttransplant outcomes.24 The impact of functional status 
assessed by KPS on outcomes related to SPKT, however, is not 
well described. To help address this knowledge gap, we sought 
to characterize the associations of KPS with patient survival in 
a large national cohort of US SPKT candidates and recipients. 
Specifically, we examined survival according to baseline KPS, 
as well as the impact of SKPT on survival (perioperatively and 
longer term) in relation to candidate functional status.
MATERIALS AND METHODS
Data Source and Sampling
This study used data from the SRTR. The SRTR sys-
tem includes data on all donors, waitlisted candidates, and 
transplant recipients in the United States, submitted by the 
members of the OPTN. The Health Resources and Services 
Administration, US Department of Health and Human 
Services, provides oversight of the activities of the OPTN and 
SRTR contractors. The primary samples included adult (age 
≥18 y) SPKT candidates and recipients from 2006 to 2019. The 
latest follow-up status date posttransplant was December 9, 
2019. Patients with unknown functional status (n = 561) were 
excluded.
Functional Status, Covariate, and Outcome 
Definitions
Functional status at the time of listing for SPKT candidates 
and at the time of transplant for SPKT recipients was defined 
by center-reported KPS (Table S1, SDC, http://links.lww.com/
TXD/A273). KPS is a categorical classification system with 
progressive but arbitrary increases in assigned performance 
status at 10% intervals without use of the intervening num-
bers and so was categorized for analysis.22,23 Patients were cat-
egorized into 4 groups: normal (80–100), capable of self-care 
(70), requires assistance (50–60), and disabled (10–40).22,23,25 
Transplant recipient clinical and demographic characteristics, 
and characteristics of the donated organ and other transplant 
factors, were defined by the OPTN Transplant Candidate 
Registration and Transplant Recipient Registration forms 
(Table 1). The primary outcome was mortality, as reported by 
transplant centers to OPTN and supplemented with the Social 
Security Death Master File. Kidney graft failure was defined 
as return to maintenance dialysis or retransplant. Pancreas 
graft failure was defined by center reporting. Graft loss was 
considered as all-cause and included graft loss due to death, 
per the methods of the SRTR.26
Outcome and Statistical Analyses
Clinical characteristics of the study sample are described as 
counts with proportions. Continuous variables were catego-
rized into clinically relevant strata. Missing categorical covari-
ate data were grouped with the absence of a characteristic 
when such categories were relevant or into a category dis-
tinct from the reference group. Missing covariate status was 
included as a regression parameter, as per our standard ana-
lytic approach.27-31 The clinical characteristics of patients with 
lower than normal functional status (caring for self, requiring 
assistance, or disability) were compared with patients with 
normal functional status using the Chi-squared test.
At-risk time for death began at the time of listing for SPKT 
candidates and at the time of transplant for SPKT recipients, 
with censoring at the last follow-up or the study end. Patient 
survival was estimated using the Kaplan-Meier method. 
At-risk time for the Kaplan-Meier estimates while on the wait-
ing list included censoring at transplant to constrain estimates 
to the period between listing and transplant. Waitlisting was 
considered the principle of intention to treat, and, therefore, 
at-risk time was not censored at removal from the waiting list 
for reasons other than transplant or death.
The adjusted association of functional status at the time of 
SPKT with mortality (adjusted hazard ratio, 95% LCLaHR95%UCL) 
and with graft failure after transplant was assessed using 
multivariable Cox proportional hazards analysis, adjusted 
for baseline recipient, donor and transplant factors (Table 2). 
Patients with normal functional status were selected as the 
reference group for comparison of the impact of KPS level. 
The association of SPKT, as a time-dependent exposure, with 
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.  3Lentine et al
mortality compared with continued waiting without trans-
plant was assessed for each functional status category using 
multivariable stratified Cox regression, including adjustment 
for other baseline clinical factors (Table S2, SDC, http://
links.lww.com/TXD/A273). Based on a priori hypothesis 
that mortality risk differs between the early and late periods 
after transplant, mortality risk associated with SPKT versus 
waiting was partitioned by time into within ≤30 and >30 
days of SPKT. A 2-sided P value of <0.05 was considered 
statistical significance. All analyses were performed using SAS 
for Windows, version 14.
RESULTS
Sample and Baseline Characteristics
Between 2006 and 2019, 16 822 eligible patients were 
listed for SPKT in the United States; 10 316 patients under-
went SPKT in the study period and 20 received a kidney 
TABLE 1.
Functional status distribution according to baseline traits among US candidates listed for SPKT, 2006–2019
 
Baseline characteristics at listing
Functional status
P value for  
Chi-square test
Normal activity Capable of self-care Requires assistance Disabled
N = 10 428 N = 3953 N = 2083 N = 358
Age, y      
 18–30 58.1 24.6 14.8 2.5 0.001
 31–44 62.2 23.6 12.2 2.0 Reference
 45–59 62.8 23.2 11.8 2.2 0.59
 ≥60 68.9 17.7 11.7 1.7 0.09
Sex      
 Male 62.1 23.5 12.2 2.2 Reference
 Female 61.8 23.5 12.6 2.1 0.88
Race      
 White 64.1 22.4 11.3 2.2 Reference
 African American 57.0 25.7 15.1 2.2 <0.0001
 Hispanic 59.6 25.0 13.8 1.6 <0.0001
 Other 65.2 23.4 8.3 3.1 0.08
Highest level of education      
 College or higher 66.7 20.9 10.6 1.8 <0.0001
 Grade/high school 55.3 27.5 14.9 2.4 Reference
Employment status      
 Working 86.4 8.7 4.6 0.3 Reference
 Not working 47.0 32.6 17.2 3.3 <0.0001
Health insurance type      
 Private 74.5 16.3 8.0 1.2 <0.0001
 Public 50.1 30.3 16.6 3.0 Reference
Body mass index, kg/m2      
 <18.5 57.0 23.8 15.0 4.2 0.13
 18.5–<25 60.3 24.5 13.0 2.3 Reference
 25–30 62.5 23.3 12.2 2.0 0.04
 >30 67.0 20.5 10.8 1.8 <0.0001
Comorbid conditions      
 Cerebral vascular disease 47.1 30.4 19.7 2.9 <0.0001
 Peripheral vascular disease 45.2 26.7 21.4 6.8 <0.0001
 COPD 58.3 18.3 20.0 3.3 0.26
 Coronary artery disease 53.5 33.4 12.2 0.88 <0.0001
ABO blood type      
 A 62.2 23.5 12.1 2.3 Reference
 AB 59.4 23.9 14.9 1.8 0.17
 B 62.7 23.6 11.6 2.1 0.89
 O 61.8 23.5 12.6 2.1 0.74
Previous transplanta 61.3 23.9 12.0 2.8 0.32
Listing y      
 2006–2010 67.9 21.6 9.4 1.1 Reference
 2011–2013 58.4 25.9 13.6 2.1 <0.0001
 2014–2016 54.7 26.1 15.1 4.1 <0.0001
 2017–2019 61.9 20.0 15.8 2.3 <0.0001
% reflect row percentages of functional status levels among patients in each baseline group. Functional status levels are based on Karnofsky Performance Score at listing: normal activity, 80–100; 
capable of self-care, 70; requires assistance, 50–60; disabled, 10–40.
aPrevious transplant may include transplant history of kidney, liver, pancreas, heart, or other organ types before the current transplant. COPD, chronic obstructive pulmonary disease; PRA, panel reactive 
antibody; SPKT, simultaneous pancreas-kidney transplantation.
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TABLE 2.
Adjusted associations of functional status at transplant and other baseline clinical factors with death and graft loss after 
SPKT
Baseline characteristics at transplant
Death Kidney graft loss Pancreas graft loss
aHR (95% CI) aHR (95% CI) aHR (95% CI)
Functional status by KPS    
 Normal activity Reference Reference Reference
 Capable of self-care 1.18 (1.00–1.41) 1.03 (0.90–1.18) 1.02 (0.91–1.15)
 Requires assistance 1.31 (1.06–1.60)a 1.18 (1.00–1.38) 1.10 (0.96–1.26)
 Disabled 1.55 (1.10–2.19)a 1.23 (0.92–1.66) 0.85 (0.65–1.13)
Age, y    
 18–30 1.21 (0.94–1.54) 1.45 (1.23–1.70)c 1.24 (1.07–1.43)a
 31–44 Reference Reference Reference
 45–59 1.29 (1.11–1.50)b 0.94 (0.83–1.06) 0.92 (0.84–1.02)
 ≥60 1.99 (1.27–3.10)a 1.33 (0.90–1.96) 0.90 (0.63–1.29)
Female 0.97 (0.84–1.13) 1.12 (1.01–1.26)a 0.99 (0.90–1.09)
Race    
 White Reference Reference Reference
 African American 0.97 (0.81–1.16) 1.21 (1.06–1.39)a 1.02 (0.91–1.15)
 Hispanic 0.67 (0.51–0.86)a 0.79 (0.65–0.96)a 0.78 (0.66–0.91)b
 Other 1.05 (0.71–1.57) 1.08 (0.79–1.48) 1.16 (0.90–1.48)
Highest level of education    
 College or higher 0.97 (0.83–1.12) 0.97 (0.86–1.08) 0.92 (0.83–1.01)
 Grade/high school Reference Reference Reference
 Missing 1.11 (0.86–1.44) 1.03 (0.84–1.26) 0.91 (0.76–1.08)
Employment status    
 Working Reference Reference Reference
 Not working 1.53 (1.26–1.86)c 1.29 (1.11–1.49)b 1.22 (1.08–1.37)b
 Missing 1.21 (0.89–1.65) 1.05 (0.84–1.32) 0.94 (0.77–1.14)
Health insurance type    
 Private 1.00 (0.85–1.18) 0.97 (0.85–1.10) 1.02 (0.91–1.13)
 Public Reference Reference Reference
 Other n/a 0.66 (0.09–4.70) n/a
Body mass index, kg/m2    
 <18.5 1.93 (1.34–2.78)b 1.20 (0.87–1.67) 1.28 (0.97–1.70)
 18.5–<25 Reference Reference Reference
 25–30 0.99 (0.85–1.16) 0.92 (0.82–1.04) 1.09 (0.99–1.21)
 >30 1.10 (0.88–1.38) 1.06 (0.89–1.25) 1.40 (1.22–1.60)c
 Missing 1.74 (1.17–2.59)a 1.37 (0.99–1.89) 1.28 (0.95–1.72)
Comorbid conditions    
 Cerebral vascular disease 1.06 (0.71–1.56) 0.93 (0.67–1.29) 0.94 (0.71–1.25)
 Peripheral vascular disease 1.18 (0.94–1.47) 1.16 (0.97–1.39) 1.04 (0.89–1.22)
 COPD 1.26 (0.41–3.94) 1.19 (0.49–2.86) 1.09 (0.52–2.30)
 Coronary artery disease 1.32 (1.02–1.72)a 1.33 (1.08–1.65)a 1.19 (0.99–1.44)
Duration of dialysis, mo    
 None (preemptive) 0.89 (0.71–1.10) 0.79 (0.67–0.93)a 0.98 (0.86–1.11)
 0–24 Reference Reference Reference
 25–60 1.16 (0.98–1.38) 1.01 (0.89–1.15) 0.96 (0.86–1.08)
 >60 1.62 (1.26–2.08)b 1.06 (0.86–1.31) 1.02 (0.84–1.22)
 Missing 1.24 (0.65–2.37) 1.49 (0.95–2.36) 1.39 (0.93–2.07)
ABO blood type    
 A Reference Reference Reference
 AB 1.15 (0.82–1.62) 1.14 (0.88–1.48) 0.97 (0.78–1.21)
 B 1.29 (1.04–1.61)a 1.22 (1.03–1.45)a 1.07 (0.93–1.23)
 O 1.11 (0.94–1.29) 1.10 (0.97–1.24) 0.96 (0.87–1.06)
Most recent PRA level    
 <10 Reference Reference Reference
 10–79 0.94 (0.75–1.19) 1.08 (0.91–1.28) 1.08 (0.93–1.25)
 ≥80 1.21 (0.77–1.91) 1.39 (0.99–1.96) 1.52 (1.12–2.07)a
 Missing 1.04 (0.77–1.41) 1.01 (0.80–1.28) 1.25 (1.04–1.50)a
(Continued)
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alone after SPKT listing. No patients received a pancreas 
alone after SPKT listing. The sample comprised 58.6% men 
and 41.4% women; racial distribution includes 62.3% white, 
21.7% African American, 12.8% Hispanic, and 3.2% other 
races (Table S2, SDC, http://links.lww.com/TXD/A273). 
Among the SPKT candidates, 62% were at normal func-
tional status, 24% were capable of self-care, 12% required 
assistance, and 2% were disabled. In contrast, among the 
SPKT recipients, 58% were at normal functional status, 
25% were capable for self-care, 14% required assistance, 
and 3% were disabled. Compared with normal functional 
status, decreased functional status (requiring assistance or 
disabled) was more common among candidates who were 
African American, had lower education level, were not 
working, or were publicly insured (Table 1). Low KPS was 
more common among SPKT candidates with, versus with-
out, cerebrovascular disease and peripheral vascular disease. 
Overall, patterns of reduced functional status among SPKT 
candidates according to baseline traits showed patterns 
similar to those observed among SPKT recipients (Table S3, 
SDC, http://links.lww.com/TXD/A273).
Association of Functional Status Levels With 
Mortality After Listing and After Transplant
A graded decline in patient survival with lower functional 
status at the time of listing was observed in SPKT candidates. 
Estimated 5-year patient survival after listing was 85.7% for 
patients with normal functional status, 82.4% for patients 
capable of self-care, 83.8% for patients requiring assistance, 
and 76.8% for patients with disability (Figure 1A). When cen-
soring for SPKT or kidney transplant alone, estimated 5-year 
patient survival on the waiting list was 77.5% for patients 
with normal functional status, 74.7% for patients capable of 
self-care, 76% for patients requiring assistance, and 65.9% 
for patients with disability (Figure 1B).
Lower functional status levels at the time of transplant 
among SPKT recipients were also associated with a graded 
decline in posttransplant survival (Figure  2). The estimated 
5-year patient survival after transplant was 91.4% for 
patients with normal functional status, 89.5% for patients 
capable of self-care, 88.4% for patients requiring assistance, 
and 85.7% for patients with disability. Compared with mor-
tality risk after SPKT for patients with normal functioning, 
after adjustment for patient, donor, and transplant factors, 
risk rose progressively for patients capable of self-care (aHR, 
1.001.181.41), requiring assistance (aHR, 1.061.311.60), and disa-
bled (aHR, 1.101.552.19) (Figure 3; Table 2). KPS at transplant 
was not significantly associated with kidney or pancreas loss 
after transplant, except that requiring assistance was associ-
ated with kidney allograft loss (aHR, 1.001.181.38).
Impact of Transplant on Patient Mortality, According 
to Functional Status at Listing
Considered from the perspective of continued waiting 
without transplant, SPKT was associated with approximately 
twice the mortality within 30 days of transplant. Associated 
risks ranged from a 75% increase for patients with normal 
functional status (aHR, 1.251.752.45) to a trend toward 2-fold 
HLA mismatches    
 Zero A, B, DR Reference Reference Reference
 Zero DR 0.48 (0.26–0.88)a 0.67 (0.40–1.13) 0.74 (0.47–1.16)
 Other mismatch 0.49 (0.28–0.84)a 0.71 (0.44–1.13) 0.72 (0.48–1.10)
Previous transplantd 1.05 (0.75–1.46) 1.14 (0.88–1.47) 1.07 (0.86–1.34)
KDPI    
 <20 Reference Reference Reference
 20–85 1.26 (1.09–1.45)b 1.24 (1.11–1.38)b 1.32(1.20–1.44)c
 >85 1.95 (0.62–6.14) 1.92 (0.79–4.67) 3.21(1.59–6.48)b
 Missing 1.36 (0.84–2.20) 1.32 (0.91–1.92) 1.82(1.39–2.38)c
Cold ischemia time, h    
 <12 Reference Reference Reference
 13–24 1.10 (0.95–1.28) 1.11 (0.99–1.25) 1.18 (1.07–1.30)b
 25–36 1.03 (0.53–2.00) 1.01 (0.60–1.68) 1.28 (0.86–1.91)
 >36 2.88 (1.47–5.65)a 1.74 (0.95–3.18) 1.59 (0.90–2.83)
 Missing 0.94 (0.69–1.26) 0.98 (0.77–1.23) 1.12 (0.92–1.37)
Transplant y    
 2006–2010 Reference Reference Reference
 2011–2013 0.77 (0.65–0.92)a 0.80 (0.70–0.91)b 0.84 (0.75–0.94)a
 2014–2016 0.61 (0.46–0.80)b 0.55 (0.45–0.68)c 0.65 (0.55–0.77)c
 2017–2019 0.46 (0.28–0.76)a 0.41 (0.28–0.61)c 0.33 (0.24–0.45)c
Graft loss is considered as all-cause, including loss from death. Functional status levels are based on Karnofsky Performance Score at transplant: normal activity, 80–100; capable of self-care, 70; 
requires assistance, 50–60; disabled, 10–40.
aP values: 0.002 to <0.05.
bP values: 0.0001 to <0.002.
cP values: <0.0001.
d Previous transplant may include transplant history of kidney, liver, pancreas, heart, or other organ types before the current transplant.
aHR, adjusted hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; KDPI, kidney donor profile index; KPS, Karnofsky Performance Score; N/a, not available; PRA, panel 
reactive antibody; SPKT, simultaneous pancreas-kidney transplantation.
TABLE 2. (Continued)
Baseline characteristics at transplant
Death Kidney graft loss Pancreas graft loss
aHR (95% CI) aHR (95% CI) aHR (95% CI)
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A
B
FIGURE 1. Patient survival after listing for SPKT without censoring for transplant (A), and while on the waiting list censored at transplant (B) 
according to functional status at listing. SPKT, simultaneous pancreas-kidney transplant.
FIGURE 2. Patient survival after SPKT according to functional status at transplant. SPKT, simultaneous pancreas-kidney transplant.
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mortality for disabled patients (aHR, 0.682.207.08), although 
statistical significance was not reached for lower functional 
status, likely due to smaller sample sizes (Figure  4A, Table 
S4, SDC, http://links.lww.com/TXD/A273). In contrast, 
beyond 30 days, SPKT was associated with reduced mor-
tality compared with continued waiting, ranging from 52% 
risk reduction for disabled patients (aHR, 0.260.480.88) to 70% 
reduction for those with normal functioning (aHR, 0.260.300.34) 
(Figure 4B).
DISCUSSION
As progressively older patients with higher comorbidity 
burdens seek and undergo transplant, measures of frailty 
including functional status are being recognized as important 
considerations in transplant practice.32 We examined the sur-
vival implications of functional status assessed by KPS, the 
only existing surrogate measure for frailty/functional status 
collected in the OPTN registry,22,24,33 in a national US cohort 
of SPKT candidates and recipients, and observed several key 
findings: (1) need for assistance or disability was reported for 
14.5% of candidates and 17.5% of recipients; (2) lower func-
tional status levels were associated with graded increases in 
mortality after listing and after transplant; (3) compared with 
continued waiting, SPKT was associated with 2-fold mortal-
ity risk within 30 days of the transplant procedure. However, 
beyond 30 days, SPKT was associated with reduced mortality, 
from 52% risk reduction for disabled patients to 70% risk 
reduction for those with normal functioning.
Recent improvements in diabetes management have 
extended life expectancy and increased the number of older 
type 1 diabetes patients living with advanced disease compli-
cations.34,35 Previous studies have demonstrated inferior out-
comes among SPKT recipients aged older than 50 years,36,37 
although more recent reports demonstrate that acceptable 
outcomes can be obtained with careful medical assessment 
and patient selection. Therefore, advanced age, in isolation, 
should not be considered an absolute exclusion criterion 
for SPKT.38-41 Frailty is more common among older dialysis 
patients and kidney transplant recipients.32,42 In our study of 
SPKT candidates and recipients, functional status distribu-
tions were fairly similar across age groups, such that reduced 
functional status was not solely a condition of the elderly. 
Prior work has reported independent associations of diabetes 
with frailty among dialysis patients.43,44 Diabetes is thought 
to contribute directly to the pathophysiology of frailty by 
increasing the risk of sarcopenia.45 Patients with type 1 dia-
betes in particular are at risk for sarcopenia due to the cata-
bolic effect of insulin deficiency and excess accumulation of 
intramyocellular lipids.46 In addition to diabetes, CKD is also 
associated with frailty through protein energy-wasting, oxi-
dative stress, and chronic inflammation.47 These mechanisms 
may explain why decreased levels of functional status were 
observed across age groups in our study of diabetic patients 
with ESKD. Importantly, our results suggest that functional 
status is an independent predictor of patient survival in SPKT 
candidates and recipients, independent of age.
Associations between reduced functional levels assessed by 
KPS and posttransplant mortality have been reported after 
deceased-donor kidney transplant,24 liver transplant,48 and 
lung transplant.49,50 We found that in the context of SPKT, 
impaired functional status (defined as KPS <70) was common 
among candidates and recipients (~15%–18%) and was asso-
ciated with increased mortality after both listing and trans-
plant. Importantly, evaluation and decision-making regarding 
suitability for SPKT is comprehensive and especially affected 
by markers of cardiovascular risk, as cardiac comorbidity is 
common in this population.51 In our study, the association 
of lower KPS with increased mortality remained significant 
in the dose-response relationship after adjusting for poten-
tial confounders available in the registry, including reported 
comorbid conditions, supporting that functional assessment is 
a relevant prognostic tool in this population. The application 
of functional assessment by KPS and possibly other measures 
of frailty in SPKT populations, in addition to comprehensive 
assessment, may improve risk stratification and target waitlist 
management attention to high-risk groups.
Beyond characterization of higher- versus lower-risk trans-
plant recipients, transplant outcomes compared with contin-
ued waiting offer an important patient-centered perspective. 
FIGURE 3. Adjusted associations of functional status at transplant with SPKT recipient mortality risk. *Adjusted for baseline factors in Table 2. 
aHR, adjusted hazard ratio; CI, confidence interval; SPKT, simultaneous pancreas-kidney transplant.
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Morbidity and mortality risks after SPKT are recognized 
to be highest within the first 3 months due to the risks of 
the surgery (such as infection, reperfusion pancreatitis, and 
enteric anastomotic leak), as well as other perioperative 
risks such as major adverse cardiac events.7,52 We found that 
risk of increased perioperative mortality was similar across 
functional status levels. However, after the perioperative risk 
period, SPKT was significantly associated with reduced long-
term mortality compared with waiting. Importantly, a survival 
benefit was found across all functional status levels, although 
benefit trended higher for patients with normal functioning 
(52% risk reduction among disabled patients versus 70% 
reduction in those with normal functioning).
Demonstration of long-term survival benefits of SPKT 
compared with waiting across all functional status groups, 
including the small number of disabled patients selected for 
transplant, is an important observation of this study. Frail 
diabetic candidates with ESKD may be deemed too ill for 
SPKT at many transplant centers, in part due to concerns for 
perioperative risks.39 Notably, the number of additions to the 
SPKT waiting list in the United States steadily declined from 
1935 in 2000 to 1228 in 2017.37,53,54 Fewer candidates are 
added to the waiting list and the number of active candidates 
decreased by more than half, from 2776 in 2002 to 1039 
in 2018.7,37,53,54 Furthermore, the number of active pancreas 
transplant centers in the United States has been declining; 
only 10 US centers performed at least 20 pancreas transplants 
in 2017, and 50% of all centers performed <6 pancreas trans-
plants in 2017.37,53,54 When SPKT is successful, the potential 
benefits of an insulin-free, dialysis-free state can be substan-
tial. In a study of 1000 SPKT recipients with 22-year follow-
up, long-term patient survival after SPKT was better than for 
all other transplant options for type 1 diabetes patients with 
ESKD, including those who underwent living donor kidney 
transplant alone.55 However, expertise and judicious selec-
tion are critical to select appropriate candidates for the pro-
cedure. Although we lacked information on evaluation and 
selection protocols in this retrospective registry study, our 
A
B
FIGURE 4. Adjusted mortality risk associated with SPKT (A) within 30 d and (B) after 30 d posttransplant, by functional status at listing. aHR, 
adjusted hazard ratio; CI, confidence interval; SPKT, simultaneous pancreas-kidney transplant.
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findings support that SPKT may be an appropriate option to 
prolong long-term survival for some carefully selected dia-
betic patients with impaired functional status. These data may 
encourage reconsideration of some patients currently deemed 
ineligible for SPKT, although selection by experienced clini-
cians remains paramount.39
This study has limitations. We conducted a retrospective 
observational study of national registry data, with the limi-
tations inherent in any such study. The benefit of SPKT may 
dominantly derive from restoration of kidney function.56 As 
patients with decreased functional status who were listed and 
underwent transplant may be selected based on clinical infor-
mation not included in the registry, these results may not be 
generalizable to all patients with lower KPS values. Notably, 
the distribution of functional status levels among SPKT candi-
dates was similar to a recent study of kidney transplant candi-
dates, although the proportion of disability was slightly lower 
among the SPKT candidates (2% versus 4% among listed 
kidney candidates).25 In addition, this is an analysis of the US 
SPKT population, and results may not generalize to SPKT 
populations in other countries. Although several frailty assess-
ment tools are being used increasingly to measure functional 
status, there is no standardized selection process for candidates 
based on these measures.42 KPS may be impacted by observer 
bias and scoring can vary within and across transplant centers. 
Nonetheless, benefits of KPS include that it is easily measured 
and identified in the national registry at listing and at the time 
of transplant. While we identified significant associations of 
KPS with survival among SPKT candidates and recipients, we 
lacked information on interventions and management strate-
gies used by centers for patients with low functional status.
In conclusion, lower center-reported functional status was 
associated with increased mortality risk among SPKT candi-
dates and recipients. However, SPKT can provide substantial 
long-term survival benefits across all functional status levels, 
compared with waiting without SPKT, for patients selected 
to undergo the procedure. For frail candidates who are oth-
erwise medically acceptable, these data raise intriguing possi-
bilities for intervention, such as targeted physical therapy and 
nutrition therapy to improve functional status, followed by 
reassessment for SPKT candidacy for those initially declined. 
Multidisciplinary involvement of physical therapy and nutri-
tional experts within the management paradigm is vital to 
strive for reductions in frailty and improved functional sta-
tus but requires coordinated participation of referring care 
providers (eg, nephrologists, endocrinologists, dialysis teams) 
and reimbursement mechanisms through insurance provid-
ers.42 Continued efforts are needed to improve and standard-
ize the measurement of functional status and frailty in this 
population, and to determine whether interventions such as 
prehabilitation can improve functional status and outcomes, 
deliver these services to patients in need, and help support 
SPKT opportunities for all patients who can benefit.
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